NEW YORK (GenomeWeb News) – Cepheid said today that it has received clearance from the US Food and Drug Administration to market its Xpert vanA test for the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci.

The 45-minute test runs on Cepheid's GeneXpert System, and is the first rapid and accurate test released in the United States for vanA, Cepheid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.